Blockchain Registration Transaction Record

Nutriband Sells Subsidiary Stake to Fund Breakthrough Abuse-Deterrent Fentanyl Patch

Nutriband sells 90% of Pocono Pharmaceutical to EarthVision Bio for $5M to fund development of AVERSA Fentanyl, the world's first abuse-deterrent fentanyl patch with $80-200M annual sales potential.

This development matters significantly because it addresses the ongoing opioid crisis by advancing technology that could prevent abuse and accidental exposure to powerful pain medications. Fentanyl patches, while effective for chronic pain management, have been subject to misuse through extraction and injection methods that bypass controlled release mechanisms. Nutriband's AVERSA technology represents a potential paradigm shift in transdermal drug delivery safety. If successful, it could set new standards for prescription opioid safety, potentially reducing overdose deaths and diversion while maintaining therapeutic benefits for legitimate patients. The substantial sales projections ($80-200 million annually) indicate both market need and commercial viability, suggesting this innovation could meaningfully impact public health while creating shareholder value. The strategic funding move through the subsidiary sale demonstrates focused resource allocation toward this critical healthcare challenge.